News
Bristol Myers Paying BioNTech Up to $11.1B in Cancer Drug Team-up
Could the world’s best-selling drug have competition on the way? American pharmaceutical giant Bristol Myers Squibb agreed Monday to pay up to $11.1 billion to partner with Germany’s BioNTech and co-develop its next-generation immunotherapy for cancer,
BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...
In the assessment of 12-month price targets, analysts unveil insights for BioNTech, presenting an average target of $138.7, a ...
Moderna is suing Pfizer and BioNTech, accusing the companies of infringing on Moderna’s patents when they partnered to develop their own COVID-19 vaccine. Moderna is suing Pfizer and ...
Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.
The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing ...
The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.
The move to pull funding for drugmaker Moderna to continue testing an mRNA vaccine intended to protect people from the bird ...
In a significant shift, more Americans now believe COVID-19 vaccines may have caused heart problems in some patients, a sign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback